Tech Center 4100 • Art Units: 1626 1699 4121
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18250404 | METHODS FOR TREATING HEMATOLOGIC MALIGNANCIES WITH AMINO-PYRROLOPYRIMIDINONE COMPOUNDS | Non-Final OA | Merck Sharp & Dohme LLC |
| 17998909 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | Purdue Research Foundation |
| 18041193 | PROTEASOME ENHANCERS AND USES THEREOF | Non-Final OA | Board of Trustees of Michigan State University |
| 18281047 | CHIRAL SYNTHONS FOR THE SYNTHESIS OF CHIRAL PHOSPHOROTHIOATES | Final Rejection | Boehringer Ingelheim International GmbH |
| 17908434 | IONTOPHORETIC COMPOSITION FOR ADMINISTERING S-KETAMINE | Final Rejection | LTS LOHMANN THERAPIE-SYSTEME AG |
| 18444414 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | Non-Final OA | UWM Research Foundation, Inc. |
| 17907324 | NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT | Non-Final OA | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 17131312 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS | Final Rejection | Boehringer Ingelheim Vetmedica GmbH |
| 18213524 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | Final Rejection | Acura Pharmaceuticals, Inc. |
| 18246979 | Hexadeca Ammonium-Modified Phthalocyanine and Preparation Method and Use Thereof as Photodynamic Drug | Non-Final OA | Fuzhou University |
| 18565204 | SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE | Non-Final OA | STINGINN INC. |
| 18549767 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | Non-Final OA | DiCE Molecules SV, Inc. |
| 18273878 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | Non-Final OA | Universite de Rennes 1 |
| 18268950 | METHODS FOR DELAY OF EJACULATION IN HUMAN MALES | Non-Final OA | Kanna Health Limited |
| 18265915 | EGANELISIB FOR USE IN THE TREATMENT OF PD-L1 NEGATIVE CANCER | Non-Final OA | Twelve Therapeutics, Inc |
| 18318192 | APPLICATION OF N1-DIHYDROCAFFEOYL-N10-CAFFEOYLSPERMIDINE IN PREPARATION OF DRUG, HEALTH PRODUCT OR FUNCTIONAL FOOD | Final Rejection | NINGXIA MEDICAL UNIVERSITY |
| 18192094 | USE OF NERIDRONIC ACID OR OF ITS SALT FOR THE TREATMENT OF OSTEOARTHROSIS | Final Rejection | ABIOGEN PHARMA S.P.A. |
| 18020966 | USE OF SORAFENIB IN TREATMENT OF TYPE 1 DIABETES | Non-Final OA | THE SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY |
| 18001427 | METHODS FOR TREATING OR PREVENTING CHRONIC KIDNEY DISEASE | Final Rejection | Arthrosi Therapeutics, Inc. |
| 17923167 | NAMPT MODULATORS | Non-Final OA | Cytokinetics, Inc. |
| 17791760 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | Final Rejection | Axial Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy